BioNTech SE has finalized a settlement with the University of Pennsylvania, involving a total payment of up to $467 million, to retain license rights under certain patents as of March 27, 2025. This agreement includes royalties from 2020-2023 and funds for a joint research initiative, but BioNTech denies any liability concerning allegations made by Penn.